Sinovac Biotech Co., Ltd: COVID-19 trials

The registry lists 30 COVID-19 studies with Sinovac Biotech Co., Ltd as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 5Phase 3 5Phase 4 15No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19RecruitingNCT06050460Phase 1
• Efficacy and Safety of SA58 Nasal Spray in Close Contact With COVID-19 PeopleStatus unknownNCT05667714Not applicable
• Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk PopulationsStatus unknownNCT05664919Not applicable
• A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide VaccineCompletedNCT05499351Phase 4
• Immunogenicity and Safety Study of One Booster Dose of Trivalent COVID-19 Vaccine (Vero Cell), InactivatedStatus unknownNCT05433272Phase 3
• Immunogenicity and Safety Study of Booster Vaccine With the COVID-19 Vaccine (Vero Cell), Inactivated, Omicron StrainCompletedNCT05411471Phase 2
• Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the ElderlyCompletedNCT05398926Phase 4
• Immunogenicity and Safety of Booster Immunization of COVID-19 Vaccine (Vero Cell), Inactivated (Omicron Variant) in Healthy People Aged 18 Years and AboveCompletedNCT05381350Phase 3
• Effectiveness of Inactivated COVID-19 Vaccine of the First Booster DoseStatus unknownNCT05367895
• Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 VaccineActive, not recruitingNCT05329038Phase 4
• Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong KongWithdrawnNCT05254236Phase 2
• Immunogenicity of an Inactivated COVID-19 VaccineCompletedNCT05198336Phase 4
• Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19CompletedNCT05165966Phase 4
• Safety and Immunogenicity Study of Booster Vaccination With COVID-19 Vaccine (Vero Cell),Inactivated From Different Manufactures for Prevention of COVID-19SuspendedNCT05165732Phase 4
• Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and AboveWithdrawnNCT05156632Phase 3
• Safety and Immunogenicity of COVID-19 Vaccine, Inactivated in Healthy Population Aged From 3 to 11 YearsCompletedNCT05137418Phase 3
• Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine Between Different Workshops in Healthy Children Aged 3-17 YearsActive, not recruitingNCT05112913Phase 4
• Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)CompletedNCT05107557Phase 4
• Safety and Immunogenicity Study of Booster Vaccination With Medium-dosage or High-dosage SARS-CoV-2 Inactivated Vaccine for Prevention of COVID-19Status unknownNCT05079217Phase 4
• Immunogenicity And Safety of COVID-19 Vaccine , Inactivated Co -Administration With EV71 Vaccine (Vero Cell)CompletedNCT04993365Phase 4
• Efficacy, Immunogenicity and Safety of COVID-19 Vaccine , Inactivated in Children and AdolescentsCompletedNCT04992260Phase 3
• Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and AdolescentsCompletedNCT04992208Phase 4
• Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican RepublicCompletedNCT04974164
• Clinical Trial of Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy AdultsStatus unknownNCT04962308Phase 4
• Immunogenicity and Safety of an Inactivated COVID-19 VaccineCompletedNCT04953325Phase 4
• Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in AdultsCompletedNCT04911790Phase 4
• Lot-to-lot Consistency of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Healthy AdultsCompletedNCT04894227Phase 4
• Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19CompletedNCT04551547Phase 1/2
• Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)CompletedNCT04383574Phase 1/2
• Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)CompletedNCT04352608Phase 1/2